No Data
D.Western Therapeutics to Collaborate on Next-Generation Eye Disease Treatments
Medrex rebounded after eight days, as the FDA accepted the application for a neuropathic pain treatment drug co-developed with DWTI.
Medrex <4586.T> rebounded for the first time in eight days after a period of no change, temporarily reaching 77 yen, which is an increase of 9 yen. After the close on the 2nd, the company announced that its group and De-Western Therapeutics Institute (DWTI) <4576.T> had resubmitted an application for new drug approval to the FDA (U.S. Food and Drug Administration) for the treatment of postherpetic neuralgia "MRX-5LBT," and it was accepted, which is viewed as noteworthy. According to the company, "MRX-5LBT" utilizes ionic liquids.
D. Western Therapeutics' Lidocaine Patch NDA Accepted by FDA
A soft trend with selling first, but a solid performance at lower prices may occur.
[Emerging Markets Individual Stock Strategy] The Emerging Markets are expected to have a weak performance today. In yesterday's U.S. stock market on the 2nd, the Dow Inc gained 235.36 dollars (+0.56%) to close at 42,225.32 dollars. Selling pressure continued as concerns over the Trump administration's announcement of reciprocal tariffs weighed on stock prices. On the other hand, the private sector ADP Employment Statistics reported growth that exceeded Financial Estimates, leading to increased buying as fears of an economic downturn eased. Additionally, the highest tariff rates were announced, with plans to lower them depending on subsequent negotiations.
Medurek, DWTI and others [Emerging Markets press release]
<4496> Commerce One has completed its acquisition of its own stocks. <4575> The period for the collaborative research agreement with the Pharma Valley project concerning CANVAS DO/TDO inhibitors has been extended. <4576> The approval application for DWTI's nerve pain treatment drug "DW-5LBT" has been accepted in the USA. <4586> Medreck MRX-5LBT: The approval application has been accepted by the USA FDA. <4884> Additional analysis of the Phase II clinical trial targeting ALS (physician-led clinical trial): Extended collaborative research with Tohoku University.
Key points of interest for the PTS on the 2nd = NARTH, F-code, Nishimatsuya, etc.
▽ NARTHE <7638.T> announced a buyback of up to 1 million shares (6.33% of the total issued shares) and 1.5 billion yen. ▽ F-code <9211.T> announced a buyback. ▽ Nishimatsuya Chain <7545.T> announced a buyback along with its standalone financial results for the period ending in February 2025. ▽ Reprocell <4978.T> was selected for "Development of Basic Technologies for Industrialization of Regenerative Medicine and Gene Therapy". ▽ DWTI <4576.T> and Medrex <4586.T> resubmitted their jointly developed project on the 神.